Press Releases

BIOMS MEDICAL RETAINS ICON FOR PIVOTAL MULTIPLE SCLEROSIS TRIAL

Edmonton, Alberta, January 26, 2006 – BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has signed a letter of intent establishing ICON (ICON; NASDAQ: ICLR) as the global clinical research organization (CRO) for the company’s ongoing pivotal phase II/III clinical trial for MBP8298 for the treatment of multiple sclerosis.

“ICON is ranked as one of the top clinical trial management firms in the world. Their expertise in this field will be invaluable as they assume the lead for our pivotal clinical trial as we expand it through Europe,” said Kevin Giese, President of BioMS Medical. “ICON has identified additional clinical trial sites in Europe that will ensure the timely completion of enrollment of our trial in mid-2006. We now anticipate up to an estimated 50 sites will be participating across Canada and Europe.”

Dr. Dan Weng, President ICON Clinical Research ROW, commented: “We are delighted BioMS has chosen ICON to conduct its pivotal trial. With our extensive experience, we are committed to ensuring the achievement of BioMS’s goals”.

The randomized, double-blind trial is targeted to enroll up to 553 patients, who will be administered either MBP8298 or placebo intravenously every six months for a period of two years.

About ICON

ICON is a global provider of development services to the pharmaceutical, biotechnology and medical device industries, specializing in the management, execution and analysis of complex, multinational clinical trials. ICON experts have successfully conducted over 2000 development projects and over 1500 consultancy engagements across major therapeutic areas. Currently, ICON has over 3000 employees, operating from 41 offices in 27 countries. For further information, please visit our website at www.iconclinical.com.

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.